IGF1R and Ewing sarcoma: Unfortunately, no convincing benefit of IGF1R pathway inhibitors has been found in these studies [27,28], except in some rare cases of a sustained response in patients with Ewing sarcoma and adrenocortical carcinoma [9,29].